Down Day For Drugmakers… And Intel Jumps On Deal Rumors 1/17/25
CNBC's "Fast Money"
00:00
Intro
This chapter explores the recent challenges faced by Novo Nordisk as its shares reach an 18-month low amid new drug price negotiations. It examines the broader implications for the obesity drug market and potential future strategies in response to evolving pricing pressures and competition.
Transcript
Play full episode
